Novel unit B cryptophycin analogues as payloads for targeted therapy

Area of Science:

• Natural Products Chemistry
• Medicinal Chemistry
• Molecular Pharmacology

Background:

• Cryptophycins are potent natural cytotoxins with significant anticancer potential.
• Targeted cancer therapy necessitates cytotoxic agents with functional groups for homing device conjugation.
• Developing novel analogues is crucial for advancing chemotherapy strategies.

Purpose of the Study:

• To design, synthesize, and biologically evaluate three new unit B cryptophycin analogues.
• To investigate the impact of specific modifications on the O-methyl group of unit B D-tyrosine.
• To explore structure-activity relationships for potential targeted drug delivery.

Main Methods:

• Chemical synthesis of three novel cryptophycin analogues with varying O-substituents on unit B.
• In vitro cytotoxicity assays to determine biological activity.
• Molecular docking studies to predict binding interactions with β-tubulin.

Main Results:

• Two analogues, featuring O-(allyloxyethyl) and O-(hydroxyethyl) moieties, retained subnanomolar cytotoxicity.
• An analogue with an O-(((azidoethoxy)ethoxy)ethoyxethyl) substituent (triethylene glycol spacer with azide) exhibited complete loss of cytotoxic activity.
• Docking studies provided structural insights correlating analogue modifications with observed cytotoxicity.

Conclusions:

• Modifications at the O-methyl position of unit B D-tyrosine can preserve cryptophycin cytotoxicity.
• The introduction of a triethylene glycol spacer with a terminal azide significantly impairs anticancer activity.
• These findings inform the design of future cryptophycin analogues for targeted cancer therapies.